FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology and specifically to reversible inhibition of hepatocellular carcinoma in tumor cells of gene expression coding synthesis of apolipoprotein B. Method involves introducing into a medium containing Huh7 tumor cells human hepatocellular carcinoma, a dispersion of lipid nanoparticles of modified magnetite crystals obtained by mixing 138 pts. wt. magnetite crystals with size of 23–27 nm with 1 pts. wt. mixture of cholesterol lipids, 1,2-distearoyl-sn-glycero-3-phosphocholine, 1,1'-(2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydecyl)amino)ethyl)piperazin-1-yl)ethylazanediyl)dododecan-2-ol and 1,2-dimyristoyl-sn-glycero-methoxy(polyethyleneglycol)-2000, taken in weight ratio of 15:7:75:3, respectively, at first with 60,000 pts. wt. chloroform, followed by 82,240 pts. wt. N-methyl-2-pyrrolidone, treatment of the mixture with ultrasound for 0.5–7.0 hours with ultrasound power of 116–580 W, removal of chloroform, addition of water in dispersion of 400–600 % of the volume of the dispersion, dialysis of the obtained dispersion against water for 24–48 hours in a dialysis bag with pore size of 25–50 kilodaltons, concentration of dispersion to content of magnetite 0.7–2.8 mg/ml under vacuum, mixing 1 pts. wt. obtained dispersion of modified magnetite crystals with a solution of low interfering ribonucleic acid in an aqueous solution of sodium acetate containing 0.05–0.20 pts. wt. low interfering ribonucleic acid, purification of the obtained dispersion by re-dialysis against water, addition of a sodium phosphate buffer into the purified dispersion to obtain a dispersion with ionic force of 0.15 M. Then one performs treatment for 1–3 h with an alternating magnetic field with inductance of 50–100 millitesla.
EFFECT: invention increases degree of reversible inhibition of gene expression coding synthesis of apolipoprotein B in tumor cells of Huh7 human hepatocellular carcinoma.
1 cl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF REVERSIBLE INHIBITION IN TUMOR CELLS OF HEPATOCELLULAR CARCINOMA OF GENE EXPRESSION CODING SYNTHESIS OF APOLIPOPROTEIN B | 2018 |
|
RU2699172C1 |
SORAFENIB-BASED COMBINATION THERAPY FOR HEPATOCELLULAR CARCINOMA | 2022 |
|
RU2800071C1 |
METHOD FOR PRODUCING MODIFIED CRYSTALS OF MAGNETITE | 2017 |
|
RU2656667C1 |
COMPOSITIONS AND METHODS FOR INHIBITION OF PROTEOLYTIC PATH OF ARGININE/N-DEGRON | 2020 |
|
RU2787841C2 |
METHOD FOR PRODUCING A SYSTEM FOR DELIVERING AN ANTICANCER AGENT TO TUMOR CELLS | 2017 |
|
RU2657835C1 |
METHOD OF T-CELL ACTIVATION/PROLIFERATION | 2019 |
|
RU2806549C2 |
COMPOSITION FOR INHIBITING GROWTH AND STIMULATION OF APOPTOSIS OF COLORECTAL CANCER CELLS | 2016 |
|
RU2644675C1 |
METHODS AND COMPONENTS FOR INDUCTION OF TUMOR- -SPECIFIC CYTOTOXICITY | 1998 |
|
RU2214280C2 |
ONCOLYTIC VIRAL VECTORS AND USE THEREOF | 2017 |
|
RU2749050C2 |
METHODS OF TREATING CANCER, HAVING HEMIZYGOUS LOSS OF TP53 | 2016 |
|
RU2721953C2 |
Authors
Dates
2019-11-01—Published
2018-12-27—Filed